Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Umbilical cord mesenchymal stem cells (UC-MSCs) are a type of cell therapy being developed by Acibadem University for the treatment of Duchenne muscular dystrophy (DMD). DMD is a genetic disorder characterized by the absence of dystrophin, leading to progressive muscle degeneration. UC-MSCs are multipotent cells that can be harvested from umbilical cord tissue and are known for their low immunogenicity and high proliferative capacity. The therapeutic rationale involves the cells' ability to migrate to damaged muscle tissue, modulate the inflammatory response, and potentially differentiate into myogenic cells or transfer wild-type dystrophin genes to host cells, thereby improving muscle function and slowing disease progression.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on umbilical cord mesenchymal stem cells (Acıbadem University).